Spherix Global Insights Amplifies the Lupus Patient Voice, Highlighting the Lengthy and Challenging Journey to Diagnosis and Treatment
Lupus patients desire more targeted information on specific treatments available, underscoring an opportunity for the pharmaceutical industry to play a more pivotal role in patient education. [Exton PA, November 8, 2023] — Spherix Global Insights recently conducted research with 306 Systemic Lupus Erythematosus (SLE) patients, delving into their personal experiences navigating the complex landscape of […]
US Neurologists Emphasize Tremendous Unmet Treatment Need in Parkinson’s Disease, According to Spherix Global Insights
Gene therapies and LRRK2 inhibition are at the forefront of prescribers’ interest, highlighting the need for a truly disease modifying therapy. [Exton PA, November 7, 2023] — Parkinson’s disease (PD) is the second-most prevalent neurodegenerative disorder following Alzheimer’s disease, affecting an estimated one million individuals in the United States1. With a significant absence of a […]
Rate of Switching from Regeneron’s Eylea to Genentech’s Vabysmo Doubled Over Past Year for Diabetic Macular Edema
Despite Vabysmo’s gains in 2023, Eylea HD will prove to be a formidable force in the coming year. [Exton PA, November 1, 2023] — As U.S. ophthalmologists increasingly embrace a wider array of treatment options, the landscape of the diabetic macular edema (DME) market has begun to evolve. Spherix Global Insights has unveiled its latest […]
US Nephrologists Embrace Current IgA Nephropathy Therapies, Yet a Thriving Pipeline Signals Fierce Market Evolution Ahead
According to Spherix Global Insights, US nephrologists have expressed a high level of enthusiasm for Novartis’ iptacopan and atrasentan, as well as Otsuka’s sibeprenlimab, placing them at the forefront of their most anticipated products awaiting approval for the treatment of IgAN. Exton, Pa., October 13, 2023 – Innovation within the IgA nephropathy (IgAN) space continues […]
Biosimilar Competition Erodes Humira’s Market Share; Amjevita Leads the Pack
With competition finally hitting the US market, branded adalimumab (Humira) is finally losing market share, according to the third quarter update of the Special Topix: Biosimilars Today and Tomorrow from Spherix Global Insights. Prior to Amgen’s adalimumab-atto (Amjevita) launching in the United States in January 2023, the reference product from AbbVie had enjoyed more than 20 years of exclusivity on […]
Greater use of Benlysta, Saphnelo seen in US, EU to treat lupus
In both the U.S. and Europe, clinicians want to limit treatment with glucocorticoids — steroid hormones whose long-term use for autoimmune diseases is tied to serious side effects — among people with moderate to severe lupus. To that end, healthcare professionals are increasingly prescribing biological therapies like Benlysta (belimumab) and Saphnelo (anifrolumab). Those are the main findings of two […]
Spherix Introduces Patient Chart Dynamix™, an Enhanced Independent Pharmaceutical Market Research Chart Audit
[Exton PA, September 26, 2023] — Spherix Global Insights, a trusted leader in pharmaceutical market research, is delighted to announce the launch of its latest product, Patient Chart Dynamix™. This innovative offering represents a significant advancement from the previously acclaimed service, RealWorld Dynamix™, featuring enhanced customization and insights. This new and improved solution is an […]
Spherix Global Insights Announces New Leadership to Drive Growth and Innovation
Pharmaceutical industry veteran Dan Barton to serve as Chief Executive Officer. Exton PA, September 21, 2023 — Spherix Global Insights, a leading provider of market data and insights to the pharmaceutical industry, is thrilled to announce the appointment of Dan Barton as Chief Executive Officer, effective September 18th. Dan is a seasoned executive with a […]
Amgen’s Amjevita Remains the Frontrunner in the US Adalimumab Biosimilars Market, Despite Increased Competition, According to Spherix Global Insights.
Boehringer Ingelheim’s Cyltezo has a slight competitive edge over other concurrent biosimilar launches on certain key performance metrics, though prescriber future projections show little differentiation in use among the recent entrants. Exton, PA, September 14, 2023 — This summer ushered in the highly anticipated introduction of a multitude of additional adalimumab biosimilars to the dynamic […]
With Little Remaining Unmet Need for Injectable Biologics for the Treatment of Plaque Psoriasis, US Dermatologists Report the Future is Oral, According to Spherix Global Insights
Despite the increased efficacy of BMS’ Sotyktu over Amgen’s Otezla, dermatologists continue to express a desire for additional oral agents that bring enhanced safety and efficacy. Exton, PA August 31, 2023 – The biologic treatment armamentarium for plaque psoriasis has arguably experienced some of the most successful developments in recent autoimmune history. With the entry […]
